Loading…
Protecting Consumer Access to Generic Drugs Act of 2007
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
62pct
17d open
vs 7,255 other HR bills in the 110th — cohort avg 47d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2009 · first_quarter · Consumer Issues/Safety/Products
Generic Drug Settlements S.316, Preserve Access to Affordable Generics Act. H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007.
Client expense: Not reported · Firm income: $6,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Medicare/Medicaid
Medicare/General. H.R. 205, H.R. 748, H.R. 1218, H.R. 1277, H.R. 1310, H.R. 1521, H.R. 2009, H.R. 2056, H.R. 2065, H.R. 2149, H.R. 3025, H.R. 3061, H.R. 3162, H.R. 3932, H.R. 6331, S. 137, S. 250, S. 450, S. 706, S. 1887, S. 2089, S. 2115, S. 2219, S. 3101: provisions relating to enrollment periods and the late enrollment penalty, physician reimbursement rates, creating a Medicare-operated prescription drug plan, drug price negotiations, Medicare beneficiary improvements, repealing cost containment mandates, Medicare Advantage payments, Medicare Advantage stabilization fund, and comparative cost adjustment demonstration projects under the Medicare Modernization Act, therapy caps, liberalizing asset test limits, reducing the Part D benefit gap and guaranteeing prescription drug benefits. Medicare/Prescription Drug Price Negotiation. H.R. 4, H.R. 118, H.R. 5317, S. 3, S. 273: provisions pertaining to the negotiation of prescription drug prices under Medicare Part D. Medicare/Medicare Advantage. H.R. 2945: provision to provide beneficiary protections against excessive cost-sharing under the Medicare Advantage Program. Medicare/Importation of Prescription Drugs. S. 242, H.R. 380, S.Amdt. 4299: provisions pertaining to the importation of prescription drugs. Medicare/Outpatient Psychiatric Services. H.R. 1571, H.R. 1663, H.R. 4897, S. 1715, S. 1854: provisions to eliminate discriminatory copayment rates for outpatient psychiatric services under Medicare Part B. Medicare/Geriatric Assessments. H.R. 2244, S. 1340: provisions to provide Medicare beneficiaries with access to geriatric assessments and chronic care coordination services. Medicare/Generic Drugs Market Exclusivity. H.R. 1432, H.R. 1902, S. 316, S. 1088: pertaining to market exclusivity for generic drugs. Medicare/Prescription Drug Benefits for Low Income Beneficiaries. H.R. 470, H.R. 932, H.R. 1536, H.R. 2058, H.R. 3127, S. 1102, S. 1103, S. 1107, S. 1108, S. 2101: provisions affecting prescription drug benefits for low-income beneficiaries under Medicare Parts B and D. Medicare/Part B Late Enrollment. H.R. 2591: provision limiting the penalty for late enrollment under Medicare Part B. Medicare/Marketing. H.R. 2307, H.R. 4790, S. 1883, S. 2687: provisions relating to the marketing of Medicare Advantage and Medicare Part D plans. Medicare/Health Care Vouchers. H.R. 749: provision to establish health care vouchers for seniors. Medicare/Medicare Savings Accounts. H.R. 2639, S. 173, S. 1019: provisions pertaining to Medicare Savings Accounts. Medicare/End-of-Life Planning. S. 464, S. 465, S. 466: pertaining to advance directives and end-of-life planning. Medicare/Means-testing. H.R. 4295, H.R. 4330, S. 2414, S.Amdt. 4240: pertaining to means-testing of Medicare Part D. Medicare/Presidents Funding Warning. H.R. 5480, S. 2662: proposals responding to the Presidents Medicare funding warning. H. Res. 1368, to suspend section 803 of the Medicare Modernization Act of 2003 (known as the Medicare trigger") for the remainder of the 110th Congress. Medicare/24-month Waiting Period. H.R.154, S. 2101: provisions phasing out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicaid/Federal Match. H.R. 5140: provisions pertaining to temporary increases in the federal Medicaid match. Medicaid/Targeted Case Management. Targeted Case Management: interim final rule to implement Section 6052 of the Deficit Medicaid/Targeted Case Management (continued). Reduction Act.
2008 · third_quarter · Medicare/Medicaid
Medicare/General. H.R. 205, H.R. 748, H.R. 1218, H.R. 1277, H.R. 1310, H.R. 1521, H.R. 2009, H.R. 2056, H.R. 2065, H.R. 2149, H.R. 3025, H.R. 3061, H.R. 3162, H.R. 3932, H.R. 6331, S. 137, S. 250, S. 450, S. 706, S. 1887, S. 2089, S. 2115, S. 2219, S. 3101: Medicare/General (continued). provisions relating to enrollment periods and the late enrollment penalty, physician reimbursement rates, creating a Medicare-operated prescription drug plan, drug price negotiations, Medicare beneficiary improvements, repealing cost containment mandates, Medicare Advantage payments, Medicare Advantage stabilization fund, and comparative cost adjustment demonstration projects under the Medicare Modernization Act, therapy caps, liberalizing asset test limits, reducing the Part D benefit gap and guaranteeing prescription drug benefits. Medicare/Prescription Drug Price Negotiation. H.R. 4, H.R. 118, H.R. 5317, S. 3, S. 273: provisions pertaining to the negotiation of prescription drug prices under Medicare Part D. Medicare/Medicare Advantage. H.R. 2945: provision to provide beneficiary protections against excessive cost-sharing under the Medicare Advantage Program. Medicare/Importation of Prescription Drugs. S. 242, H.R. 380, S.Amdt. 4299: provisions pertaining to the importation of prescription drugs. Medicare/Outpatient Psychiatric Services. H.R. 1571, H.R. 1663, H.R. 4897, S. 1715, S. 1854: provisions to eliminate discriminatory copayment rates for outpatient psychiatric services under Medicare Part B. Medicare/Geriatric Assessments. H.R. 2244, S. 1340: provisions to provide Medicare beneficiaries with access to geriatric assessments and chronic care coordination services. Medicare/Generic Drugs Market Exclusivity. H.R. 1432, H.R. 1902, S. 316, S. 1088: pertaining to market exclusivity for generic drugs. Medicare/Prescription Drug Benefits for Low Income Beneficiaries. H.R. 470, H.R. 932, H.R. 1536, H.R. 2058, H.R. 3127, S. 1102, S. 1103, S. 1107, S. 1108, S. 2101: provisions affecting prescription drug benefits for low-income beneficiaries under Medicare Parts B and D. Medicare/Part B Late Enrollment. H.R. 2591: provision limiting the penalty for late enrollment under Medicare Part B. Medicare/Marketing. H.R. 2307, H.R. 4790, S. 1883, S. 2687: provisions relating to the marketing of Medicare Advantage and Medicare Part D plans. Medicare/Health Care Vouchers. H.R. 749: provision to establish health care vouchers for seniors. Medicare/Medicare Savings Accounts. H.R. 2639, S. 173, S. 1019: provisions pertaining to Medicare Savings Accounts. Medicare/End-of-Life Planning. S. 464, S. 465, S. 466: pertaining to advance directives and end-of-life planning. Medicare/Means-testing. H.R. 4295, H.R. 4330, S. 2414, S.Amdt. 4240: pertaining to means-testing of Medicare Part D. Medicare/Presidents Funding Warning. H.R. 5480, S. 2662: proposals responding to the Presidents Medicare funding warning. H. Res. 1368, to suspend section 803 of the Medicare Modernization Act of 2003 (known as the Medicare trigger") for the remainder of the 110th Congress. Medicare/24-month Waiting Period. H.R.154, S. 2101: provisions phasing out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicare/Identity Theft Prevention. H.R. 6600, provisions related to removal of Social Security numbers from Medicare cards. Medicaid/Federal Match. H.R. 5140: provisions pertaining to temporary increases in the federal Medicaid match. Medicaid/Targeted Case Management. Targeted Case Management: interim final rule to implement Section 6052 of the Deficit Reduction Act.
2008 · second_quarter · Medicare/Medicaid
Medicare/General. H.R. 205, H.R. 748, H.R. 1218, H.R. 1277, H.R. 1310, H.R. 1521, H.R. 2009, H.R. 2056, H.R. 2065, H.R. 2149, H.R. 3025, H.R. 3061, H.R. 3162, H.R. 3932, H.R. 6331, S. 137, S. 250, S. 450, S. 706, S. 1887, S. 2089, S. 2115, S. 2219, S. 3101: provisions relating to enrollment periods and the late enrollment penalty, physician reimbursement rates, creating a Medicare-operated prescription drug plan, drug price negotiations, Medicare beneficiary improvements, repealing cost containment mandates, Medicare Advantage payments, Medicare Advantage stabilization fund, and comparative cost adjustment demonstration projects under the Medicare Modernization Act, therapy caps, liberalizing asset test limits, reducing the Part D benefit gap and guaranteeing prescription drug benefits. Medicare/Prescription Drug Price Negotiation. H.R. 4, H.R. 118, H.R. 5317, S. 3, S. 273: provisions pertaining to the negotiation of prescription drug prices under Medicare Part D. Medicare/Medicare Advantage. H.R. 2945: provision to provide beneficiary protections against excessive cost-sharing under the Medicare Advantage Program. Medicare/Importation of Prescription Drugs. S. 242, H.R. 380, S.Amdt. 4299: provisions pertaining to the importation of prescription drugs. Medicare/Outpatient Psychiatric Services. H.R. 1571, H.R. 1663, H.R. 4897, S. 1715, S. 1854: provisions to eliminate discriminatory copayment rates for outpatient psychiatric services under Medicare Part B. Medicare/Geriatric Assessments. H.R. 2244, S. 1340: provisions to provide Medicare beneficiaries with access to geriatric assessments and chronic care coordination services. Medicare/Generic Drugs Market Exclusivity. H.R. 1432, H.R. 1902, S. 316, S. 1088: pertaining to market exclusivity for generic drugs. Medicare/Prescription Drug Benefits for Low Income Beneficiaries. H.R. 470, H.R. 932, H.R. 1536, H.R. 2058, H.R. 3127, S. 1102, S. 1103, S. 1107, S. 1108, S. 2101: provisions affecting prescription drug benefits for low-income beneficiaries under Medicare Parts B and D. Medicare/Part B Late Enrollment. H.R. 2591: provision limiting the penalty for late enrollment under Medicare Part B. Medicare/Marketing. H.R. 2307, H.R. 4790, S. 1883, S. 2687: provisions relating to the marketing of Medicare Advantage and Medicare Part D plans. Medicare/Health Care Vouchers. H.R. 749: provision to establish health care vouchers for seniors. Medicare/Medicare Savings Accounts. H.R. 2639, S. 173, S. 1019: provisions pertaining to Medicare Savings Accounts. Medicare/End-of-Life Planning. S. 464, S. 465, S. 466: pertaining to advance directives and end-of-life planning. Medicare/Means-testing. H.R. 4295, H.R. 4330, S. 2414, S.Amdt. 4240: pertaining to means-testing of Medicare Part D. Medicare/Presidents Funding Warning. H.R. 5480, S. 2662: proposals responding to the Presidents Medicare funding warning. Medicare/24-month Waiting Period. H.R.154, S. 2101: provisions phasing out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicaid/Federal Match. H.R. 5140: provisions pertaining to temporary increases in the federal Medicaid match. Medicaid/Targeted Case Management. Targeted Case Management: Interim final rule to implement Section 6052 of the Deficit Reduction Act.
2008 · first_quarter · Medicare/Medicaid
Medicare/General. H.R. 205, H.R. 748, H.R. 1218, H.R. 1277, H.R. 1310, H.R. 1521, H.R. 2009, H.R. 2056, H.R. 2065, H.R. 2149, H.R. 3025, H.R. 3061, H.R. 3162, H.R. 3932, S. 137, S. 250, S. 450, S. 706, S. 1887, S. 2089, S. 2115, S. 2219: provisions relating to enrollment periods and the late enrollment penalty, physician reimbursement rates, creating a Medicare-operated prescription drug plan, drug price negotiations, Medicare beneficiary improvements, repealing cost containment mandates, Medicare Advantage payments, Medicare Advantage stabilization fund, and comparative cost adjustment demonstration projects under the Medicare Modernization Act, therapy caps, liberalizing asset test limits, Medicare Secondary Payer clarification, reducing the Part D benefit gap and guaranteeing prescription drug benefits. Medicare/Prescription Drug Price Negotiation. H.R. 4, H.R. 118, H.R. 5317, S. 3, S. 273: provisions pertaining to the negotiation of prescription drug prices under Medicare Part D. Medicare/Medicare Advantage. H.R. 2945: provision to provide beneficiary protections against excessive cost-sharing under the Medicare Advantage Program. Medicare/Importation of Prescription Drugs. S. 242, H.R. 380, S.Amdt. 4299: provisions pertaining to the importation of prescription drugs. Medicare/Outpatient Psychiatric Services. H.R. 1571, H.R. 1663, H.R. 4897, S. 1715, S. 1854: provisions to eliminate discriminatory copayment rates for outpatient psychiatric services under Medicare Part B. Medicare/Geriatric Assessments. H.R. 2244, S. 1340: provisions to provide Medicare beneficiaries with access to geriatric assessments and chronic care coordination services. Medicare/Generic Drugs Market Exclusivity. H.R. 1432, H.R. 1902, S. 316, S. 1088: pertaining to market exclusivity for generic drugs. Medicare/Prescription Drug Benefits for Low Income Beneficiaries. H.R. 470, H.R. 932, H.R. 1536, H.R. 2058, H.R. 3127, S. 1102, S. 1103, S. 1107, S. 1108, S. 2101: provisions affecting prescription drug benefits for low-income beneficiaries under Medicare Parts B and D. Medicare/Part B Late Enrollment. H.R. 2591: provision limiting the penalty for late enrollment under Medicare Part B. Medicare/Marketing. H.R. 2307, H.R. 4790, S. 1883, S. 2687: provisions relating to the marketing of Medicare Advantage and Medicare Part D plans. Medicare/Health Care Vouchers. H.R. 749: provision to establish health care vouchers for seniors. Medicare/Medicare Savings Accounts. H.R. 2639, S. 173, S. 1019: provisions pertaining to Medicare Savings Accounts. Medicare/End-of-Life Planning. S. 464, S. 465, S. 466: pertaining to advance directives and end-of-life planning. Medicare/Means-testing. H.R. 4295, H.R. 4330, S. 2414, S.Amdt. 4240: pertaining to means-testing of Medicare Part D. Medicare/Presidents Funding Warning. H.R. 5480, S. 2662: proposals responding to the Presidents Medicare funding warning. Medicare/24-month Waiting Period. H.R.154, S. 2101: provisions phasing out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicaid/Federal Match. H.R. 5140: provisions pertaining to temporary increases in the federal Medicaid match. Medicaid/Targeted Case Management. Targeted Case Management: interim final rule to implement Section 6052 of the Deficit Reduction Act.
| Democratic |
| TX |
| Chris Van Hollen | Democratic | MD |
| Diana DeGette | Democratic | CO |
| Edward J. Markey | Democratic | MA |
| G. K. Butterfield | Democratic | NC |
| Henry A. Waxman | Democratic | CA |
| James Marshall | Democratic | GA |
| Janice D. Schakowsky | Democratic | IL |
| John D. Dingell | Democratic | MI |
| Michael F. Doyle | Democratic | PA |
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $480,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
H.R.1908, S.1145 Patent Reform Act of 2007 H.R.806 To Amend the FD&C Act to Prohibit the Marketing of Authorized Generics S.438 Fair Prescription Drug Competition Act H.R.1038, S.623 Access to Life Saving Medicines Act H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007 H.R.5629 Pathway for Biosimilars Act H.R.1902 Protecting Consumers Access to Generic Drugs Act of 2007 S.316 Preserve Access to Affordable Generics Act
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
Advance proposal to create an FDA process for the approval of generic biological products; S. 316 - Preserve Access to Affordable Generics Act; H.R. 1902 - Protecting Consumer Access to Generic Drugs Act; H.R. 1038 - Access to Life Saving Medicine Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
HR. 1432, Preserve Access to Affordable Generics Act (settlements) 3/07 S. 316, Preserve Access to Affordable Generics Act (settlements) 3/07 HR 1902, Protecting Consumer Access to Generic Drugs Act (4/07) S 2300, Lower PRICED Drugs Act, legislation pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To Amend Title 35, United States Code, to confirm certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 438, Fair Prescription Drug Competition Act (ban authorized generics) 1/07 HR 780, Counterfeit Drug Prevention Act of 2007 3/07 HR 1908, Patent Reform Act of 2007 S 1145, Patent Reform Act of 2007 S 623, Access to Life-Saving Medication Act (FOBS) 2/07 HR 1038, Access to Life-Saving Medication Act HR 5629, Pathway For Biosimilars Act S. 1145, Patent Reform Act (4/07) HR 1908, Patent Reform Act S. 3325, PL-110-403 (10/13/08) Intellectual Property Enforcement Act
Client expense: $3,250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · fourth_quarter · Copyright/Patent/Trademark
Patent Reform Act of 2008 (S. 3600), Patent Reform Act of 2007 (H.R. 1908 & S. 1145) Preserve Access to Affordable Generics Act (H.R. 1432 & S. 316), Protecting Consumer Access to Generic Drugs Act (H.R 1902), To amend the Federal Food, Drug, and Cosmetic Act to establish requirements for certain petitions submitted to the Food and Drug Administration, and for other purposes (S. 25).
Client expense: Not reported · Firm income: $40,000
Government targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2008 · fourth_quarter · Copyright/Patent/Trademark
H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007: patent settlements H.R. 1908, Patent Reform Act of 2007: patent system reform and related issues such as obtaining/opposing patents and remedies H.R. 4279, Prioritizing Resources and Organization for Intellectual Property Act of 2007: enforcement S. 316, Preserve Access to Affordable Generics Act: patent settlements S. 522, Intellectual Property Rights Enforcement Act: anti-counterfeiting and enforcement S. 1145, Patent Reform Act of 2007: patent system reform and related issues such as obtaining/opposing patents and remedies S. 2317, Intellectual Property Enforcement Act of 2007: enforcement S. 3325, Prioritizing Resources and Organization for Intellectual Property Act of 2008: enforcement S. 3464, International Intellectual Property Protection and Enforcement Act of 2008: enforcement S. 3600, Patent Reform Act of 2008: patent system reform and related issues such as obtaining/opposing patents and remedies International intellectual property issues
Client expense: $6,170,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · fourth_quarter · Consumer Issues/Safety/Products
Generic Drug Settlements S.316, Preserve Access to Affordable Generics Act. H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
S. 316, the Preserve Access to Affordable Pharmaceuticals Act H.R. 1902, the Protecting Consumer Access to Generic Drugs Act H.R. 1038, the Access to Life Savings Medicine Act H.R. 5629, the Pathway for Biosimilars Act S. 1695, the Biologivs Price Competition and Innovation Act H.R. 5829, the Safeguarding America's Pharmaceuticals Act H.R. 3610, the Food and Drug Import Safety Act, Section 4 User Fees Regarding Drug Safety PL 110-85, the Food and Drug Amendments Act of 2007, Title VIII Clinical Trials Abbreviated New Drug Applicatin No. 76-396 for calcitonin salmon nasal spray
Client expense: $120,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
H.R. 1432 - Preserve Access to Affordable Generics Act S. 316 - Preserve Access to Affordable Generics Act H.R. 1908 - Patent Reform Act of 2007 S. 1145 - Patent Reform Act of 2007 H.R. 1902 - Protecting Consumer Access to Generic Drugs Act S. 25 - To amend the Federal Food, Drug, and Cosmetic Act to establish requirements for certain petitions submitted to the Food and Drug Administration, and for other purposes. S. 3600 - Patent Reform Act of 2008
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S 623/HR 1038 (Access to Life Saving Medicine Act), HR 1956 (Patient Protection and Innovative Biologic Medicines Act of 2007), HR 5629 (Pathway for Biosimilars Act) - Lobbied to ensure that Waxman Biogenerics legislation is enacted particularly provisions related to ensuring a safe, effective pathway for the approval of comparable, interchangeable biologics. HR 1902 (Protecting Consumer Access to Generic Drugs Act of 2007)/ S 316 (Preserve Access to Affordable Generics Act -Provisions related to preventing abuses in patent settlements between generic and brand name prescription drug manufactures. S 1145 Patient Reform Act of 2007- Ensuring that the existing inequitable conduct provisions in Patent Law Act are not weakened. Discussion regarding prescription drug affordability (no Bill). S 3230 Labor/HHS/Education Appropriations FY 2009 - Lobbying for spending levels for Rx comparative effectiveness. S 3289 Agriculture and Rural Development Appropriations, FY 2009 - Lobbied to reduce FDA generic drug processing backlog.
Client expense: $6,870,000 · Firm income: Not reported
Government targets: Administration on Aging, Commerce, Dept of (DOC), Equal Employment Opportunity Commission (EEOC), Federal Communications Commission (FCC), Federal Reserve System, Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Social Security Administration (SSA), Treasury, Dept of, White House Office
2008 · fourth_quarter · Pharmacy
HR 1038/HR 1956/HR5629--creation of a regulatory pathway for generic biologics S 1088/S 28/S 316/HR 1902--issues related to bringing generics to market in a timely fashion S. 596/S 980/HR 6353--internet pharmacy regulations HR 5839--issues relating to prescription drug pedigree/drug safety
Client expense: $430,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Legal Services Corporation, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
2008 · fourth_quarter · Medicare/Medicaid
Medicare/General. H.R. 205, H.R. 748, H.R. 1218, H.R. 1277, H.R. 1310, H.R. 1521, H.R. 2009, H.R. 2056, H.R. 2065, H.R. 2149, H.R. 3025, H.R. 3061, H.R. 3162, H.R. 3932, H.R. 6331, S. 137, S. 250, S. 450, S. 706, S. 1887, S. 2089, S. 2115, S. 2219, S. 3101: provisions relating to enrollment periods and the late enrollment penalty, physician reimbursement rates, creating a Medicare-operated prescription drug plan, drug price negotiations, Medicare beneficiary improvements, repealing cost containment mandates, Medicare Advantage payments, Medicare Advantage stabilization fund, and comparative cost adjustment demonstration projects under the Medicare Modernization Act, therapy caps, liberalizing asset test limits, reducing the Part D benefit gap and guaranteeing prescription drug benefits. Medicare/Prescription Drug Price Negotiation. H.R. 4, H.R. 118, H.R. 5317, S. 3, S. 273: provisions pertaining to the negotiation of prescription drug prices under Medicare Part D. Medicare/Medicare Advantage. H.R. 2945: provision to provide beneficiary protections against excessive cost-sharing under the Medicare Advantage Program. Medicare/Importation of Prescription Drugs. S. 242, H.R. 380, S.Amdt. 4299: provisions pertaining to the importation of prescription drugs. Medicare/Outpatient Psychiatric Services. H.R. 1571, H.R. 1663, H.R. 4897, S. 1715, S. 1854: provisions to eliminate discriminatory copayment rates for outpatient psychiatric services under Medicare Part B. Medicare/Geriatric Assessments. H.R. 2244, S. 1340: provisions to provide Medicare beneficiaries with access to geriatric assessments and chronic care coordination services. Medicare/Generic Drugs Market Exclusivity. H.R. 1432, H.R. 1902, S. 316, S. 1088: pertaining to market exclusivity for generic drugs. Medicare/Prescription Drug Benefits for Low Income Beneficiaries. H.R. 470, H.R. 932, H.R. 1536, H.R. 2058, H.R. 3127, S. 1102, S. 1103, S. 1107, S. 1108, S. 2101: provisions affecting prescription drug benefits for low-income beneficiaries under Medicare Parts B and D. Medicare/Part B Late Enrollment. H.R. 2591: provision limiting the penalty for late enrollment under Medicare Part B. Medicare/Marketing. H.R. 2307, H.R. 4790, S. 1883, S. 2687: provisions relating to the marketing of Medicare Advantage and Medicare Part D plans. Medicare/Health Care Vouchers. H.R. 749: provision to establish health care vouchers for seniors. Medicare/Medicare Savings Accounts. H.R. 2639, S. 173, S. 1019: provisions pertaining to Medicare Savings Accounts. Medicare/End-of-Life Planning. S. 464, S. 465, S. 466: pertaining to advance directives and end-of-life planning. Medicare/Means-testing. H.R. 4295, H.R. 4330, S. 2414, S.Amdt. 4240: pertaining to means-testing of Medicare Part D. Medicare/Presidents Funding Warning. H.R. 5480, S. 2662: proposals responding to the Presidents Medicare funding warning. H. Res. 1368, to suspend section 803 of the Medicare Modernization Act of 2003 (known as the Medicare trigger") for the remainder of the 110th Congress. Medicare/24-month Waiting Period. H.R.154, S. 2101: provisions phasing out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicaid/Federal Match. H.R. 5140: provisions pertaining to temporary increases in the federal Medicaid match. Medicaid/Targeted Case Management. Targeted Case Management: interim final rule to implement Section 6052 of the Deficit Medicaid/Targeted Case Management (continued). Reduction Act.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
H.R.1908, S.1145 Patent Reform Act of 2007 H.R.806 To Amend the FD&C Act to Prohibit the Marketing of Authorized Generics S.438 Fair Prescription Drug Competition Act H.R.1038, S.623 Access to Life Saving Medicines Act H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007 H.R.5629 Pathway for Biosimilars Act H.R.1902 Protecting Consumers Access to Generic Drugs Act of 2007 S.316 Preserve Access to Affordable Generics Act
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
H.R.1908, S.1145 Patent Reform Act of 2007 H.R.806 To Amend the FD&C Act to Prohibit the Marketing of Authorized Generics S.438 Fair Prescription Drug Competition Act H.R.1038, S.623 Access to Life Saving Medicines Act H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007 H.R.5629 Pathway for Biosimilars Act H.R.1902 Protecting Consumers Access to Generic Drugs Act of 2007 S.316 Preserve Access to Affordable Generics Act
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
Patent Reform, including but not limited to: S.1145, S.3600, and H.R.1908 Patent Settlements/Reverse Payments, including but not limited to: S.316, H.R.1432, and H.R.1902 Special 301 Report International Intellectual Property Issues Patent Process Issues, including but not limited to: S.3560, H.R.1778, and H.R.6344 Any other matter that relates to acess to generic drugs
Client expense: $539,634 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2008 · fourth_quarter · Health Issues
Advance proposal to create an FDA process for the approval of generic biological products; S. 316 - Preserve Access to Affordable Generics Act; H.R. 1902 - Protecting Consumer Access to Generic Drugs Act; H.R. 1038 - Access to Life Saving Medicine Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
H.R. 1038 & S. 623, Access to Life-Saving Medicine Act; H.R. 1956, Patient Protection & Innovative Biologic Medicines Act; H.R. 5629, Pathway for Biosimilars Act; S. 316, Preserve Access to Affordable Generics Act; H.R. 1902, Protecting Consumer Access to Generic Drugs Act; Development of "Pedigree" or National Drug Trafficking System; H.R. 2900, Food & Drug Administration Amendments Act; H.R. 1980 & S. 1145, Patent Reform Act; FDA Globalization Act; Tax Incentives/Extensions (R&D Tax Credit)
Client expense: $1,560,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2008 · third_quarter · Copyright/Patent/Trademark
HR. 1432, Preserve Access to Affordable Generics Act (settlements) 3/07 S. 316, Preserve Access to Affordable Generics Act (settlements) 3/07 HR 1902, Protecting Consumer Access to Generic Drugs Act (4/07) S 2300, Lower PRICED Drugs Act, legislation pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To Amend Title 35, United States Code, to confirm certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 438, Fair Prescription Drug Competition Act (ban authorized generics) 1/07 HR 780, Counterfeit Drug Prevention Act of 2007 3/07 HR 1908, Patent Reform Act of 2007 S 1145, Patent Reform Act of 2007 S 623, Access to Life-Saving Medication Act (FOBS) 2/07 HR 1038, Access to Life-Saving Medication Act HR 5629, Pathway For Biosimilars Act S. 1145, Patent Reform Act (4/07) HR 1908, Patent Reform Act
Client expense: $3,070,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · third_quarter · Copyright/Patent/Trademark
HR. 1432, Preserve Access to Affordable Generics Act (settlements) 3/07 S. 316, Preserve Access to Affordable Generics Act (settlements) 3/07 HR 1902, Protecting Consumer Access to Generic Drugs Act (4/07) S 2300, Lower PRICED Drugs Act, legislation pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To Amend Title 35, United States Code, to confirm certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 438, Fair Prescription Drug Competition Act (ban authorized generics) 1/07 HR 780, Counterfeit Drug Prevention Act of 2007 3/07 HR 1908, Patent Reform Act of 2007 S 1145, Patent Reform Act of 2007 S 623, Access to Life-Saving Medication Act (FOBS) 2/07 HR 1038, Access to Life-Saving Medication Act HR 5629, Pathway For Biosimilars Act S. 1145, Patent Reform Act (4/07) HR 1908, Patent Reform Act
Client expense: $3,060,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · third_quarter · Copyright/Patent/Trademark
H.R.1908, S.1145 Patent Reform Act of 2007 H.R.806 To Amend the FD&C Act to Prohibit the Marketing of Authorized Generics S.438 Fair Prescription Drug Competition Act H.R.1038, S.623 Access to Life Saving Medicines Act H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007 H.R.5629 Pathway for Biosimilars Act H.R.1902 Protecting Consumers Access to Generic Drugs Act of 2007 S.316 Preserve Access to Affordable Generics Act
Client expense: $155,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2008 · third_quarter · Copyright/Patent/Trademark
Patent Reform Act of 2008 (S. 3600), Patent Reform Act of 2007 (H.R. 1908 & S. 1145) Preserve Access to Affordable Generics Act (H.R. 1432 & S. 316), Protecting Consumer Access to Generic Drugs Act (H.R 1902), To amend the Federal Food, Drug, and Cosmetic Act to establish requirements for certain petitions submitted to the Food and Drug Administration, and for other purposes (S. 25).
Client expense: Not reported · Firm income: $40,000
Government targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2008 · third_quarter · Copyright/Patent/Trademark
H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007: patent settlements H.R. 1908, Patent Reform Act of 2007: patent issues H.R. 4279, Prioritizing Resources and Organization for Intellectual Property Act of 2007: enforcement S. 316, Preserve Access to Affordable Generics Act: patent settlements S. 522, Intellectual Property Rights Enforcement Act: anti-counterfeiting and enforcement S. 1145, Patent Reform Act of 2007: patent issues S.2317, Intellectual Property Enforcement Act of 2007: enforcement S.3325, Prioritizing Resources and Organization for Intellectual Property Act of 2008: enforcement S.3600, Patent Reform Act of 2008: patent reform and related issues International intellectual property issues
Client expense: $5,420,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · third_quarter · Copyright/Patent/Trademark
Patent Reform, including but not limited to: S.1145, S.3600, and H.R.1908 Patent Settlements/Reverse Payments, including but not limited to: S.316, H.R.1432, and H.R.1902 Special 301 Report International Intellectual Property Issues Patent Process Issues, including but not limited to: S.3560, H.R.1778 and H.R.6344 Any other matter that relates to access to generic drugs
Client expense: $506,976 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2008 · third_quarter · Copyright/Patent/Trademark
H.R. 1432 - Preserve Access to Affordable Generics Act S. 316 - Preserve Access to Affordable Generics Act H.R. 1908 - Patent Reform Act of 2007 S. 1145 - Patent Reform Act of 2007 H.R. 1902 - Protecting Consumer Access to Generic Drugs Act S. 25 - To amend the Federal Food, Drug, and Cosmetic Act to establish requirements for certain petitions submitted to the Food and Drug Administration, and for other purposes. S. 3600 - Patent Reform Act of 2008
Client expense: $570,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · third_quarter · Health Issues
H.R.1038 & S.623, Access to Life-Saving Medicine Act; H.R.1956, Patient Protection & Innvoative Biologic Medicines Act; H.R.5629, Pathway for Biosimilars Act; S.316, Preserve Access to Affordable Generics Act; H.R.1902, Protecting Consumer Access to Generic Drugs Act; Development of "Pedigree" or Nat'l Drug Trafficking Sytems; H.R.2900, Food & Drug Administration Amendments Act; H.R.1908 & S.1145, Patent Reform Act; FDA Globalization Act; Tax Incentives/Extensions for R&D Tax Credit.
Client expense: $1,530,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2008 · third_quarter · Consumer Issues/Safety/Products
Generic Drug Settlements S.316, Preserve Access to Affordable Generics Act. H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
S 623/HR 1038 (Access to Life Saving Medicine Act), HR 1956 (Patient Protection and Innovative Biologic Medicines Act of 2007), HR 5629 (Pathway for Biosimilars Act) - Lobbied to ensure that Waxman Biogenerics legislation is enacted particularly provisions related to ensuring a safe, effective pathway for the approval of comparable, interchangeable biologics. HR 1902 (Protecting Consumer Access to Generic Drugs Act of 2007)/ S 316 (Preserve Access to Affordable Generics Act -Provisions related to preventing abuses in patent settlements between generic and brand name prescription drug manufactures. S 1145 Patient Reform Act of 2007- Ensuring that the existing inequitable conduct provisions in Patent Law Act are not weakened. Discussion regarding prescription drug affordability (no Bill). S 3230 Labor/HHS/Education Appropriations FY 2009 - Lobbying for spending levels for Rx comparative effectiveness. S 3289 Agriculture and Rural Development Appropriations, FY 2009 - Lobbied to reduce FDA generic drug processing backlog.
Client expense: $7,330,000 · Firm income: Not reported
Government targets: Administration on Aging, Commerce, Dept of (DOC), Equal Employment Opportunity Commission (EEOC), Federal Communications Commission (FCC), Federal Reserve System, Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Social Security Administration (SSA), Treasury, Dept of, White House Office
2008 · third_quarter · Copyright/Patent/Trademark
Lobbying issues - Settlement of patent infringement claims, including S. 316, the "Preserve Access to Affordable Generics Act"; H.R. 1902, the "Protecting Consumer Access to Generic Drugs Act of 2007"; and H.R. 1432, the "Preserve Access to Affordable Generics Act."
Client expense: Not reported · Firm income: Not reported
2008 · third_quarter · Pharmacy
S. 316, the Preserve Access to Affordable Pharmaceuticals Act HR 1902, the Protecting Consumer Access to Generic Drugs Act HR 1038, the Access to Life Savings Medicine Act HR 5629, the Pathway for Biosimilars Act S. 1695, the Biologics Price Competition and Innovation Act HR 5829, the Safeguarding America's Pharmaceuticals Act HR 3610, the Food and Drug Import Safety Act, Section 4 User Fees Regarding Drug Safety PL 110-85, the Foord and Drug Amendments Act of 2007, Section 914, Citizen Petition and petition for stay of agency action PL 110-85, the Food and Drug Amendments Act of 2007. Title VIII, Clinical Trial Databases HR 6432, Animal Drug User Fee Amendments of 2008, Section 301, Consideration of Certain Petitions Combating anti-generic substitution legislation in the states Abbreviated New Drug Application No. 76-396 for calcitonin salmon nasal spray
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · third_quarter · Pharmacy
HR 1038/HR 1956/S 1695/HR 5629--creation of a regulatory pathway for generic biologics S 1088/S 28/S 316/HR 1902--Issues related to bringing generics to market in a timely fashion S. 596/S. 980/HR 6353--internet pharmacy regulations HR 5839--issues relating to prescription drug pedigree/drug safety
Client expense: $240,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
2008 · third_quarter · Health Issues
Advance proposal to create an FDA process for the approval of generic biological products; S. 316 - Preserve Access to Affordable Generics Act; H.R. 1902 - Protecting Consumer Access to Generic Drugs Act; H.R. 1038 - Access to Life Saving Medicine Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · third_quarter · Medicare/Medicaid
Medicare/General. H.R. 205, H.R. 748, H.R. 1218, H.R. 1277, H.R. 1310, H.R. 1521, H.R. 2009, H.R. 2056, H.R. 2065, H.R. 2149, H.R. 3025, H.R. 3061, H.R. 3162, H.R. 3932, H.R. 6331, S. 137, S. 250, S. 450, S. 706, S. 1887, S. 2089, S. 2115, S. 2219, S. 3101: Medicare/General (continued). provisions relating to enrollment periods and the late enrollment penalty, physician reimbursement rates, creating a Medicare-operated prescription drug plan, drug price negotiations, Medicare beneficiary improvements, repealing cost containment mandates, Medicare Advantage payments, Medicare Advantage stabilization fund, and comparative cost adjustment demonstration projects under the Medicare Modernization Act, therapy caps, liberalizing asset test limits, reducing the Part D benefit gap and guaranteeing prescription drug benefits. Medicare/Prescription Drug Price Negotiation. H.R. 4, H.R. 118, H.R. 5317, S. 3, S. 273: provisions pertaining to the negotiation of prescription drug prices under Medicare Part D. Medicare/Medicare Advantage. H.R. 2945: provision to provide beneficiary protections against excessive cost-sharing under the Medicare Advantage Program. Medicare/Importation of Prescription Drugs. S. 242, H.R. 380, S.Amdt. 4299: provisions pertaining to the importation of prescription drugs. Medicare/Outpatient Psychiatric Services. H.R. 1571, H.R. 1663, H.R. 4897, S. 1715, S. 1854: provisions to eliminate discriminatory copayment rates for outpatient psychiatric services under Medicare Part B. Medicare/Geriatric Assessments. H.R. 2244, S. 1340: provisions to provide Medicare beneficiaries with access to geriatric assessments and chronic care coordination services. Medicare/Generic Drugs Market Exclusivity. H.R. 1432, H.R. 1902, S. 316, S. 1088: pertaining to market exclusivity for generic drugs. Medicare/Prescription Drug Benefits for Low Income Beneficiaries. H.R. 470, H.R. 932, H.R. 1536, H.R. 2058, H.R. 3127, S. 1102, S. 1103, S. 1107, S. 1108, S. 2101: provisions affecting prescription drug benefits for low-income beneficiaries under Medicare Parts B and D. Medicare/Part B Late Enrollment. H.R. 2591: provision limiting the penalty for late enrollment under Medicare Part B. Medicare/Marketing. H.R. 2307, H.R. 4790, S. 1883, S. 2687: provisions relating to the marketing of Medicare Advantage and Medicare Part D plans. Medicare/Health Care Vouchers. H.R. 749: provision to establish health care vouchers for seniors. Medicare/Medicare Savings Accounts. H.R. 2639, S. 173, S. 1019: provisions pertaining to Medicare Savings Accounts. Medicare/End-of-Life Planning. S. 464, S. 465, S. 466: pertaining to advance directives and end-of-life planning. Medicare/Means-testing. H.R. 4295, H.R. 4330, S. 2414, S.Amdt. 4240: pertaining to means-testing of Medicare Part D. Medicare/Presidents Funding Warning. H.R. 5480, S. 2662: proposals responding to the Presidents Medicare funding warning. H. Res. 1368, to suspend section 803 of the Medicare Modernization Act of 2003 (known as the Medicare trigger") for the remainder of the 110th Congress. Medicare/24-month Waiting Period. H.R.154, S. 2101: provisions phasing out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicare/Identity Theft Prevention. H.R. 6600, provisions related to removal of Social Security numbers from Medicare cards. Medicaid/Federal Match. H.R. 5140: provisions pertaining to temporary increases in the federal Medicaid match. Medicaid/Targeted Case Management. Targeted Case Management: interim final rule to implement Section 6052 of the Deficit Reduction Act.
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · third_quarter · Pharmacy
H.R. 3700 Fair Medicaid Drug Payment Act of 2007, provisions related to regulation of generic drugs and consumer access; H.R. 1902 Protecting Consumer Access to Generic Drugs Act of 2007, all provisions related to generic drug consumer access; H.R. 3610 Food and Drug Import Safety Act of 2007, provisions related to drug safety.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · second_quarter · Pharmacy
S 316, the Preserve Access to Affordable Generics Act HR 1902, the Protecting Consumer Access to Generic Drugs Act HR 1038, the Access to Life Saving Medicine Act HR 5629, the Pathway for Biosimilars Act S 1695, the Biologics Price Competition and Innovation Act HR 5839, the Safeguarding America's Pharmaceuticals Act HR 3610, the Food and Drug Import Safety Act, Section 4, User Fees Regarding Drug Safety Draft Senate food and drug import safety legislation PL 110-85, the Food and Drug Amendments Act of 2007, Section 914, Citizen Petitions and petitions for stay of agency action Combating anti-generic subsitution legislation in the states
Client expense: $130,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
2008 · second_quarter · Copyright/Patent/Trademark
H.R.1908, S.1145 Patent Reform Act of 2007 H.R.806 To Amend the FD&C Act to Prohibit the Marketing of Authorized Generics S.438 Fair Prescription Drug Competition Act H.R.1038, S.623 Access to Life Saving Medicines Act H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007 H.R.5629 Pathway for Biosimilars Act H.R.1902 Protecting Consumers Access to Generic Drugs Act of 2007 S.316 Preserve Access to Affordable Generics Act
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2008 · second_quarter · Copyright/Patent/Trademark
HR. 1432, Preserve Access to Affordable Generics Act (settlements) 3/07 S. 316, Preserve Access to Affordable Generics Act (settlements) 3/07 HR 1902, Protecting Consumer Access to Generic Drugs Act (4/07) S 2300, Lower PRICED Drugs Act, legislation pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To Amend Title 35, United States Code, to confirm certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 438, Fair Prescription Drug Competition Act (ban authorized generics) 1/07 HR 780, Counterfeit Drug Prevention Act of 2007 3/07 HR 1908, Patent Reform Act of 2007 S 1145, Patent Reform Act of 2007 S 623, Access to Life-Saving Medication Act (FOBS) 2/07 HR 1038, Access to Life-Saving Medication Act HR 5629, Pathway For Biosimilars Act S. 1145, Patent Reform Act (4/07) HR 1908, Patent Reform Act
Client expense: $3,060,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · second_quarter · Pharmacy
H.R. 3700 Fair Medicaid Drug Payment Act of 2007, provisions related to regulation of generic drugs and consumer access; H.R. 1902 Protecting Consumer Access to Generic Drugs Act of 2007, all provisions related to generic drug consumer access; H.R. 3610 Food and Drug Import Safety Act of 2007, provisions related to drug safety; H.R. 5629 Pathway for Biosimilars Act, all provisions related to FDA licensure of biogeneric drugs
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
S 623/HR 1038 (Access to Life Saving Medicine Act), HR 1956 (Patient Protection and Innovative Biologic Medicines Act of 2007), HR 5629 (Pathway for Biosimilars Act) - Lobbied to ensure that Waxman Biogenerics legislation is enacted particularly provisions related to ensuring a safe, effective pathway for the approval of comparable, interchangeable biologics. HR 1902 (Protecting Consumer Access to Generic Drugs Act of 2007)/ S 316 (Preserve Access to Affordable Generics Act -Provisions related to preventing abuses in patent settlements between generic and brand name prescription drug manufactures. S 1145 Patient Reform Act of 2007- Ensuring that the existing inequitable conduct provisions in Patent Law Act are not weakened. Discussion regarding prescription drug affordability (no Bill). S 3230 Labor/HHS/Education Appropriations FY 2009 - Lobbying for spending levels for Rx comparative effectiveness and to reduce FDA generic drug processing backlog.
Client expense: $6,480,000 · Firm income: Not reported
Government targets: Administration on Aging, Commerce, Dept of (DOC), Equal Employment Opportunity Commission (EEOC), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Social Security Administration (SSA), Treasury, Dept of, White House Office
2008 · second_quarter · Health Issues
H.R. 1038 & S. 623, Access to Life-Saving Medicine Act; H.R. 1956, Patient Protection & Innovative Biologic Medicines Act; H.R. 5629, Pathway for Biosimilars Act; S. 316, Preserve Access to Affordable Generics Act; H.R. 1902, Protecting Consumer Access to Generic Drugs Act; Development of "Pedigree" or National Drug Trafficking System; H.R. 2900, Food & Drug Adminsitration Amendments Act; H.R. 1908 & S. 1145, Patent Reform Act; FDA Globalization Act; Tax Incentives/Extensions - R&D Tax Credit
Client expense: $1,530,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2008 · second_quarter · Copyright/Patent/Trademark
H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007: patent settlements H.R. 1908, Patent Reform Act of 2007: patent issues H.R. 4279, Prioritizing Resources and Organization for Intellectual Property Act of 2007: enforcement S. 316, Preserve Access to Affordable Generics Act: patent settlements S. 522, Intellectual Property Rights Enforcement Act: anti-counterfeiting and enforcement S. 1145, Patent Reform Act of 2007: patent issues S. 2317, Intellectual Property Enforcement Act of 2007: enforcement Senate reauthorization of the Federal Trade Commission (no bill introduced during reporting period) International intellectual property issues
Client expense: $5,020,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
H.R. 1432 - Preserve Access to Affordable Generics Act S. 316 - Preserve Access to Affordable Generics Act H.R. 1908 - Patent Reform Act of 2007 S. 1145 - Patent Reform Act of 2007 H.R. 1902 - Protecting Consumer Access to Generic Drugs Act S. 25 - To amend the Federal Food, Drug, and Cosmetic Act to establish requirements for certain petitions submitted to the Food and Drug Administration, and for other purposes.
Client expense: $490,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · second_quarter · Pharmacy
Items relating to the implementation of PL 110-85, the FDA reauthorization Act of 2007 HR 1038/HR 1956/S. 1695/HR 5629--regulatory pathway for generic biologics S. 1088/S. 28/S. 316/HR 1902--Issues related to bringing generics to market in a timely fashion S. 596/S. 980--internet pharmacy regulations Issues relating to the DOL's proposed disclosure of compensation for service fee providers under ERISA
Client expense: $210,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), SENATE, White House Office
2008 · second_quarter · Copyright/Patent/Trademark
Patent Reform, including but not limited to: S.1145 and H.R.1908 Patent Settlements/Reverse Payments, including but not limited to: S.316, H.R.1432, and H.R.1902 Special 301 Report Patent Process Issues, including but not limited to: H.R.1778 and H.R.6344 International Intellectual Property Issues Any other matter that relates to access to generic drugs
Client expense: $459,139 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2008 · second_quarter · Health Issues
Advance proposal to create an FDA processs for the approval of generic biological products. S. 316 - Preserve Access to Affordable Generics Act; H.R. 1902 - Protecting Consumer Access to Generic Drugs Act; H.R. 1038 - Access to Life Saving Medicine Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · second_quarter · Copyright/Patent/Trademark
H.R. 1432 - Preserve Access to Affordable Generics Act, S. 316 - Preserve Access to Affordable Generics Act,H.R. 1908 - Patent Reform Act of 2007, S. 1145 - Patent Reform Act of 2007, H.R. 1902 - Protecting Consumer Access to Generic Drugs Act
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
Lobbying issues - Settlement of patent infringement claims, including S. 316, the "Preserve Access to Affordable Generics Act"; H.R. 1902, the "Protecting Consumer Access to Generic Drugs Act of 2007"; and H.R. 1432, the "Preserve Access to Affordable Generics Act."
Client expense: Not reported · Firm income: $10,000
Government targets: Congressional Budget Office (CBO)